CLAIMS

What is claimed is:

1. An antibody or a recombinant antibody comprising a heavy chain variable region (V_H) having at least 80% identity to amino acid sequence SEQ ID NO: 8 and a light chain variable region (V_L) having at least 80% identity to amino acid sequence SEQ ID NO: 7.

2. The antibody or the recombinant antibody of claim 1, comprising the V_L having at least 85% identity to amino acid sequence SEQ ID NO: 7.

3. The antibody or the recombinant antibody of claim 1, comprising the V_L having at least 90% identity to amino acid sequence SEQ ID NO: 7.

4. The antibody or the recombinant antibody of claim 1, comprising the V_L having at least 95% identity to amino acid sequence SEQ ID NO: 7.

5. The antibody or the recombinant antibody of claim 1, comprising the V_L having at least 99% identity to amino acid sequence SEQ ID NO: 7.

6. The antibody or the recombinant antibody of claim 1, comprising the V_L having at least 100% identity to amino acid sequence SEQ ID NO: 7.

7. The antibody or the recombinant antibody of any one of claims 1-6, comprising the V_H having at least 85% identity to amino acid sequence SEQ ID NO: 8.

8. The antibody or the recombinant antibody of any one of claims 1-6, comprising the V_H having at least 90% identity to amino acid sequence SEQ ID NO: 8.

9. The antibody or the recombinant antibody of any one of claims 1-6, comprising the V_H having at least 95% identity to amino acid sequence SEQ ID NO: 8.

10. The antibody or the recombinant antibody of any one of claims 1-6, comprising the V_H having at least 99% identity to amino acid sequence SEQ ID NO: 8.

11. The antibody or the recombinant antibody of any one of claims 1-6, comprising the V_H having at least 100% identity to amino acid sequence SEQ ID NO: 8.

12. The antibody or a recombinant antibody of any one of claims 1-11, comprising a heavy chain sequence comprising a complementarity determining region (CDR) H1 having at least 80% identity to amino acid sequence SEQ ID NO: 4, a CDR H2 having at least 80% identity to amino acid sequence SEQ ID NO: 5, and a CDR H3 having at least 80% identity to amino acid sequence SEQ ID NO: 6, and a light chain sequence comprising a CDR L1 having at least 80% identity to amino acid sequence SEQ ID NO: 1, a CDR L2 having at least 80% identity to amino acid sequence SEQ ID NO: 2, and a CDR L3 having at least 80% identity to amino acid sequence SEQ ID NO: 3.

13. The antibody or the recombinant antibody of claim 12 in which the CDR L1 has at least 85% identity to amino acid sequence SEQ ID NO: 1, the CDR L2 has at least 85% identity to amino acid sequence SEQ ID NO: 2, and the CDR L3 has at least 85% identity to amino acid sequence SEQ ID NO: 3.

14. The antibody or the recombinant antibody of claim 12 in which the CDR L1 has at least 90% identity to amino acid sequence SEQ ID NO: 1, the CDR L2 has at least 90% identity to amino acid sequence SEQ ID NO: 2, and the CDR L3 has at least 90% identity to amino acid sequence SEQ ID NO: 3.

15. The antibody or the recombinant antibody of claim 12 in which the CDR L1 has at least 95% identity to amino acid sequence SEQ ID NO: 1, the CDR L2 has at least 95% identity to amino acid sequence SEQ ID NO: 2, and the CDR L3 has at least 95% identity to amino acid sequence SEQ ID NO: 3.

16. The antibody or the recombinant antibody of claim 12 in which the CDR L1 has at least 99% identity to amino acid sequence SEQ ID NO: 1, the CDR L2 has at least 99% identity to amino acid sequence SEQ ID NO: 2, and the CDR L3 has at least 99% identity to amino acid sequence SEQ ID NO: 3.

17. The antibody or the recombinant antibody of claim 12 in which the CDR L1 has at least 100% identity to amino acid sequence SEQ ID NO: 1, the CDR L2 has at least 100% identity to amino acid sequence SEQ ID NO: 2, and the CDR L3 has at least 100% identity to amino acid sequence SEQ ID NO: 3.

18. The antibody or the recombinant antibody of any one of claims 12-17 in which the CDR H1 has at least 85% identity to amino acid sequence SEQ ID NO: 4, the CDR H2 has at least 85% identity to amino acid sequence SEQ ID NO: 5, and the CDR H3 has at least 85% identity to amino acid sequence SEQ ID NO: 6.

19. The antibody or the recombinant antibody of any one of claims 12-17 in which the CDR H1 has at least 90% identity to amino acid sequence SEQ ID NO: 4, the CDR H2 has at least 90% identity to amino acid sequence SEQ ID NO: 5, and the CDR H3 has at least 90% identity to amino acid sequence SEQ ID NO: 6.

20. The antibody or the recombinant antibody of any one of claims 12-17 in which the CDR H1 has at least 95% identity to amino acid sequence SEQ ID NO: 4, the CDR H2 has at least 95% identity to amino acid sequence SEQ ID NO: 5, and the CDR H3 has at least 95% identity to amino acid sequence SEQ ID NO: 6.

21. The antibody or the recombinant antibody of any one of claims 12-17 in which the CDR H1 has at least 99% identity to amino acid sequence SEQ ID NO: 4, the CDR H2 has at least 99% identity to amino acid sequence SEQ ID NO: 5, and the CDR H3 has at least 99% identity to amino acid sequence SEQ ID NO: 6.

22. The antibody or the recombinant antibody of any one of claims 12-17 in which the CDR H1 has at least 100% identity to amino acid sequence SEQ ID NO: 4, the CDR H2 has at least 100% identity to amino acid sequence SEQ ID NO: 5, and the CDR H3 has at least 100% identity to amino acid sequence SEQ ID NO: 6.

23. The antibody or the recombinant antibody according to any one of claims 1-22, further comprising a human heavy chain constant region or a human light chain constant region.

24. The antibody or the recombinant antibody of claim 23, wherein the human heavy chain constant region is IgG1 or IgG4 or a fragment thereof.

25. The antibody or the recombinant antibody of any one of claims 1-24, wherein the heavy chain has at least 80% identity to the amino acid sequence of SEQ ID NO: 10.

26. The antibody or the recombinant antibody of any one of claims 1-25, wherein the light chain

has at least 80% identity to the amino acid sequence of SEQ ID NO: 9.

27. The antibody or the recombinant antibody of any one of claims 1-22, comprising human a human variable framework region and a murine constant region.

28. The antibody or the recombinant antibody according to any one of claims 1-27, wherein the antibody or the recombinant antibody specifically binds to a CD163 epitope comprising amino acid sequence SEQ ID NO: 18.

29. The antibody or the recombinant antibody according to any one of claims 1-271-117, wherein the antibody or the recombinant antibody specifically binds to a CD163 epitope comprising amino acid sequence SEQ ID NO: 19.

30. The antibody or the recombinant antibody according to any one of claims 1-27, wherein the antibody or the recombinant antibody specifically binds to a CD163 epitope comprising amino acid sequence SEQ ID NO: 20.

31. The antibody or the recombinant antibody according to any one of claims 1-27, wherein the antibody or the recombinant antibody specifically binds to a CD163 epitope comprising each of amino acid sequence SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.

32. A pharmaceutical composition, comprising an antibody or a recombinant antibody according to any one of claims 1-31 and a pharmaceutically acceptable excipient.

33. Use of an antibody or a recombinant antibody according to any one of claims 1-31, for the manufacture of a medicament for treating cancer in a human subject.

34. The antibody or the recombinant antibody according to any one of claims 1-31 or the pharmaceutical composition of claim 32 for use in therapy.